Related Experiment Video
Updated: May 16, 2026

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Potential biomarker for aspirin use in colorectal cancer therapy
Ruth E Langley1, Peter M Rothwell
1MRC Clinical Trials Unit, Aviation House, 125 Kingsway, London WC2B 6NH, UK.
Abstract:
Patients with colorectal cancer with mutated PIK3CA, identified from two large observational cohorts, had increased cancer-specific and overall survival if they used aspirin regularly after diagnosis compared to non-users. No effect of aspirin was seen in patients with wild-type PIK3CA. Mutated PIK3CA might be a useful biomarker to select patients who would benefit from adjuvant aspirin therapy.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Drugs for Treatment of Ulcerative Colitis in IBD
